Showing 3211-3220 of 5805 results for "".
- New Retinoid Foam Wins FDA Approvalhttps://practicaldermatology.com/news/20120514-new_retinoid_foam_wins_fda_approval/2459805/The FDA has approved Fabior (tazarotene) Foam, 0.1%, for the treatment of acne vulgaris in patients 12 years and older. The approval was based on two multi-center, randomized, double-blind, vehicle-controlled pivotal Phase 3 studies, in which a total of 1,485 patients with moderate-to-severe acne vu
- Provectus Pharmaceuticals' PV-10 Phase 2 Final Data To Be Presentedhttps://practicaldermatology.com/news/20120509-provectus_pharmaceuticals_pv-10_phase_2_final_data_to_be_presented/2459806/Phase 2 final data on PV-10 for metastatic melanoma by Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) will be presented at the second European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanom
- Novartis Acquires Fougera Pharma for $1.5 Billionhttps://practicaldermatology.com/news/20120504-novartis_acquires_fougera_pharma_for_15_billion/2459809/With it's $1.5 billion acquisition of US-based Fougera Pharmaceuticals, Novartis will be the biggest maker of dermatologic generics in the country. The Fougera products will add to those of Novartis's existing generics unit Sandoz.
- Ouchless Needle Announces First Exclusive International Distribution Agreement with Device Technologieshttps://practicaldermatology.com/news/20120501-ouchless_needle_announces_first_exclusive_international_distribution_agreement_with_device_technologies/2459811/Ouchless Needle by the BellaNovus Development Company announced their first international exclusive distribution agreement with Device Technologies for Australia and New Zealand. Developed by aesthetic plastic surgery innovator Marc J. Sa
- FDA Seeks More Information on Pliaglishttps://practicaldermatology.com/news/20120419-fda_seeks_more_information_on_pliaglis/2459818/FDA's Complete Response Letter to Galderma Laboratories LP outlines additional information the FDA requires before it will approve the sNDA for Pliaglis, developer Nuvo Research, Inc. reports. The response is to the supplemental New Drug App
- FDA's 45-day TV ad reviewhttps://practicaldermatology.com/news/20120313-fdas_45-day_tv_ad_review_shot_clock_in_guidance/2459846/TV ads for most prescription drugs must be submitted to FDA for pre-review 45 days before the manufacturer intends to air them, according to an FDA draft guidance in tomorrow's Federal Register. The guidance isn't a bolt from the blue but rather a case of the agency catching up on old business – i
- Cellceutix Files pre-IND Submission for Prurisol for Psoriasishttps://practicaldermatology.com/news/20120312-cellceutix_files_pre-ind_submission_for_prurisol_for_psoriasis/2459849/Cellceutix Corporation (OTCBB: CTIX) filed a pre-IND submission with the FDA for Prurisol (also termed KM-133), a drug in development for treatment of psoriasis. The company is seeking guidance to attain approval for a section 505(b)(2) designa
- FDA Approves Differin Pumphttps://practicaldermatology.com/news/20120308-fda_approves_differin_pump/2459851/FDA approved a new pump dispenser for Galderma's Differin Gel 0.3% (adapalene). The new pump dispenser will be available in pharmacies by prescription in the second quarter. According to results of a recent preference survey, involving 291 physicia
- Health Care Fraud Prevention and Enforcement Efforts Net Nearly $4.1Bhttps://practicaldermatology.com/news/20120302-health_care_fraud_prevention_and_enforcement_efforts_net_nearly_41b/2459856/Attorney General Eric Holder and Department of Health and Human Services (HHS) Secretary Kathleen Sebelius today released a new report showing that the government's health care fraud prevention and enforcement efforts recovered nearly $4.1 billion in taxpayer dollars in Fiscal Year (FY) 2011. This
- FDA Approves Methoxsalen USP Providerhttps://practicaldermatology.com/news/20120229-fda_approves_methoxsalen_usp_provider/2459859/FDA has approved a secondary supplier of Methoxsalen USP, prescribed under the brand name Oxsoralen-Ultra® (methoxsalen) Capsules, USP, 10mg. Valeant Dermatology, a division of Valeant Pharmaceuticals North America LLC, and marketer of the